Google used Cloud Next ‘26 to unveil Gemini Enterprise Agent Platform and new eighth-generation TPUs, saying customers are pushing AI deeper into enterprise workflows as token usage climbs sharply.
AWS has launched Amazon Bio Discovery, an AI application aimed at speeding early-stage drug research. Amazon says Memorial Sloan Kettering used the system to compress an antibody design process from a year into weeks, an early signal that AI drug discovery is moving from pitch decks to workflow.
Google used its April 22 Cloud Next event to introduce eighth-generation Tensor Processing Units designed for the next wave of enterprise AI agents, pairing them with new Gemini Enterprise tools and security products. The announcement highlights how the AI race is shifting from model launches toward the infrastructure needed to run them at scale.
OpenAI’s latest leadership changes are more than a personnel story. The company is shedding two senior figures tied to science research and video generation just weeks after it said it was cutting back on “side quests,” a sign it is tightening its focus around enterprise AI and core commercial products.
OpenAI released ChatGPT Images 2.0 on April 21, 2026, a significant update to its image generation system that expands support for more complex prompts, broader aspect ratios and a new “thinking” mode. The company is positioning the tool for practical use inside ChatGPT and Codex rather than one-off image generation.
OpenAI is briefing U.S. federal agencies, state governments and Five Eyes allies on GPT-5.4-Cyber, a cybersecurity-focused model it rolled out under tiered access last week. The move widens the company’s push into defensive security work as governments and banks race to test where advanced AI can help find flaws without increasing risk.
OpenAI has introduced GPT-5.4-Cyber, a variant of its latest flagship model tuned for defensive cybersecurity work, and is limiting access to vetted users through an expanded Trusted Access for Cyber program. The release puts a more capable model in the hands of security teams while keeping distribution tightly controlled.
OpenAI on April 16 introduced GPT-Rosalind, a frontier reasoning model built for drug discovery, genomics analysis, protein reasoning and other scientific research tasks. The release expands OpenAI’s push beyond general-purpose assistants into specialized workflows where long-context reasoning, data handling and domain-specific analysis can carry direct commercial and research value.
OpenAI is widening Codex from a popular developer tool into a more formal enterprise offering, launching Codex Labs and teaming with large systems integrators to help customers move the product from pilots into production.
OpenAI on April 14 expanded its Trusted Access for Cyber program and introduced GPT-5.4-Cyber for vetted defenders, a move that broadens access to more permissive security tooling while keeping the rollout limited to verified users and teams.
